# Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

> **NCT02345863** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 66 (actual)

## Conditions studied

- Chronic Lymphocytic Leucemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** GA101
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02345863
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-16
- **Primary completion:** 2016-08-22
- **Final completion:** 2019-03-29
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345863, "Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02345863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*